Dr. Paul G. Rubinstein, MD

Dr. Rubinstein practices at University of Illinois Hospital in Chicago, Illinois, part of University of Illinois System.

Dr. Rubinstein's NPI, 1356518534, was assigned on May 15, 2008. Dr. Rubinstein graduated from Chicago College of Medicine and Surgery in 2003. Dr. Rubinstein holds Illinois license 036-116237.

Dr. Rubinstein's primary practice is University of Illinois Hospital, at 1740 West Taylor St Suite 1400, Chicago, IL 60612 in Cook County. The practice phone is (312) 996-3900.

Dr. Rubinstein's primary practice is University of Illinois Hospital in Chicago, Illinois, part of University of Illinois System. The medical group on file is University of Illinois Physicians Group (UIPG). Dmand AI also links Dr. Rubinstein to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rubinstein practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Rubinstein's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Rubinstein is licensed in Illinois.

CMS data shows 145 Medicare services from Dr. Rubinstein across 3 procedure codes in 2024, for 75 Medicare patients. Medicare paid $7,509 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 75 Medicare patients who saw Dr. Rubinstein in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have high blood pressure, and 64% have high cholesterol. 59% are also on Medicaid. Their average risk score is 2.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rubinstein's median patient age at 62, with 52% women.

In 2024, Dr. Rubinstein wrote 127 Medicare Part D claims for 22 patients. 55% of them were for generic drugs. CMS names the drug for 75 of them, across 4 drugs with 11 or more claims each, at $636,943 in total drug cost. In 2023, CMS named 97 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Rubinstein for performance year 2024, reported as part of a group. Dr. Rubinstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 19 papers to Dr. Rubinstein, published from 2010 to 2024. 2024 was the busiest year, with 3. The most frequent topics are HIV Infections, Antineoplastic Combined Chemotherapy Protocols and Brentuximab Vedotin. Dr. Rubinstein has published most often in AIDS. Dr. Rubinstein's most frequent co-authors are Juan C. Ramos, MD, Lee Ratner, MD and David M. Aboulafia, MD.

Dmand AI links Dr. Rubinstein to 9 clinical trials, 3 of them phase 1 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell and Acquired Immunodeficiency Syndrome. AIDS Malignancy Consortium sponsors the most, 4.

CMS Open Payments shows 54 general payments to Dr. Rubinstein from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 44% of the total. Seagen Inc. paid the most, $13,230.

Dr. Rubinstein graduated from Chicago College of Medicine and Surgery in 2003.